EANM

Perspective Therapeutics Reports Third Quarter Fiscal 2023 Results and Recent Business Highlights

Retrieved on: 
Tuesday, November 14, 2023

Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.

Key Points: 
  • Two additional patients were enrolled in the third quarter for a total of 9 GEP-NET patients and 2 medullary thyroid cancer (MTC) patients.
  • Third quarter 2023 revenue was the highest since the second quarter of 2022, with a return to growth over the third quarter of 2022.
  • Total operating expenses for the quarter ended September 30, 2023 were $11.3 million, compared to $4.6 million for the same period in 2022, an increase of 144%.
  • Cash and cash equivalents as of September 30, 2023 was $18.0 million as compared to $43.9 million on December 31, 2022.

United Imaging Healthcare debuts Next-Generation PET/CT Systems, the uMI Panorama Family, and the Integrated Molecular Technology Platform at EANM

Retrieved on: 
Thursday, September 21, 2023

VIENNA, Sept. 21, 2023 /PRNewswire/ -- United Imaging Healthcare, a global leader in advanced medical imaging and radiotherapy equipment, introduces its next-generation PET/CT systems, the uMI Panorama™, and the integrated molecular technology platform named uExcel, at the European Association of Nuclear Medicine (EANM) 2023 annual meeting taking place from September 9-12 in Vienna, Austria. As the sponsor of the "EANM Young Authors' Award" and "EANM Technologist Award" this year, United Imaging is playing a significant role in driving innovation in the field of molecular imaging and nuclear medicine on a global scale.

Key Points: 
  • The new wide-bore uMI Panorama is a family of products that includes the uMI Panorama, the uMI Panorama GS, and the NeuroEXPLORER.
  • The uMI Panorama GS, deriving its name from the term "Gold Standard", was born to set the gold standard in molecular imaging and revolutionize whole-body PET imaging.
  • In tandem with uMI Panorama, the uExcel, is an advanced molecular imaging technology platform meticulously integrated with both hardware and software components.
  • (Note: The uMI Panorama and the uMI Panorama GS are CE pending, not commercially available yet.

Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting

Retrieved on: 
Wednesday, September 13, 2023

These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .

Key Points: 
  • These data will be presented at the European Association of Nuclear Medicine (EANM) Annual Meeting, held September 9–13 in Vienna, Austria and can be accessed here .
  • The data show the ability of Molecular Partners to substantially increase tumor uptake of RDT candidates through an adjustment of systemic half-life, achieved by binding to the common blood protein serum albumin.
  • With today’s data we show that tuning of half-life can substantially impact the tumor uptake of our Radio DARPins,” said Patrick Amstutz, Ph.D., CEO of Molecular Partners.
  • Molecular Partners continues to progress its RDT platform and portfolio of projects, both in-house and in partnership with Novartis.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Perspective Therapeutics Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, September 11, 2023

SEATTLE, WA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced the presentation of preclinical data from two independent studies at the World Molecular Imaging Congress (WMIC) 2023, held on September 5-9, 2023, in Prague, Czech Republic, and the 36th Annual Congress of the European Association of Nuclear Medicine (EANM) in Vienna, Austria, from September 9-13, 2023.

Key Points: 
  • Dr. Michael K. Schultz, Chief Scientific Officer at Perspective Therapeutics, presented research at the WWIC on the potential of lead-based targeted alpha particle therapy using [212Pb]VMT-α-NET for the treatment of neuroendocrine tumors (NETs).
  • The study was carried out by Dr. Dongyoul Lee, an assistant professor at the Korea Military Academy.
  • The dose depositions in tumor and normal organs were estimated based on 203Pb biodistribution data.
  • In addition, tumor progression, survival rates, and body weight changes over a 120-day period were assessed, and favorable radiochemical characteristics were observed.

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

Retrieved on: 
Thursday, September 7, 2023

The main objective of the study is to establish a recommended Phase 2 dose and schedule.

Key Points: 
  • The main objective of the study is to establish a recommended Phase 2 dose and schedule.
  • Both the diagnostic agent and therapeutic drug contain Ariceum's proprietary peptide satoreotide, a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SST2), a cell surface protein often overexpressed in certain cancers including small cell lung cancer (SCLC).
  • Further details on the study can be found on Australian Clinical Trials , under identifier Ariceum SSO11O-01.
  • We believe that our lead targeted systemic radiopharmaceutical product satoreotide has the potential to demonstrate positive results in patients with extensive stage small cell lung cancer.

NUCLIDIUM to Present Data from Three Clinical-Ready Precision Oncology Programs at the 36th Annual EANM Congress

Retrieved on: 
Tuesday, September 5, 2023

NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.

Key Points: 
  • NUCLIDIUM today announced the presentation of pre-clinical and clinical translation data from three of the company’s precision oncology programs targeting epithelial tumours (KaliosTM), neuroendocrine tumours (TraceNETTM) and prostate cancer (NuriProTM) at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM), 09-13 September 2023.
  • The data, presented in two oral presentations and a poster presentation, support the advancement of these three programs into clinical translation.
  • The programs are part of NUCLIDIUM’s comprehensive pipeline of copper-based radiotheranostics based on its flexible CuTraceTM platform.
  • The positive pre-clinical data for the diagnostic candidates from three of our programs and the preparation for clinical translation represent an important step for NUCLIDIUM.

Lantheus Announces Top Rated Oral Presentation Featuring PYLARIFY AI™ at the 2023 European Association of Nuclear Medicine (EANM) Annual Meeting

Retrieved on: 
Friday, September 1, 2023

BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria.

Key Points: 
  • BEDFORD, Mass., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the upcoming 2023 European Association of Nuclear Medicine (EANM) Annual Meeting, which will be held September 9-13, 2023 in Vienna, Austria.
  • PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using PYLARIFY® (piflufolastat F18) PET/CT.1 Standardized PSMA PET reporting provides consistent and precise disease burden quantification in support of patient management and tracking over time.2,3,4
    “With the increased availability of PSMA scanning for disease monitoring, the recognition and demand for better standardization and quantitative reports for PSMA PET has significantly heightened,” said Etienne Montagut, Chief Business Officer, Lantheus.
  • “We are thrilled to have Dr. Duriseti present the latest development for our PSMA AI platform, which allows consistent and accurate reporting of change in disease burden in total body PSMA PET/CT.
  • By harnessing our deep learning algorithm and extensive PSMA datasets, we are committed to sustaining our efforts to improve guidance for prostate cancer patient diagnosis and treatment.”
    Top Rated Oral Presentation details are as follows:
    Session Title: Clinical Oncology Track - TROP Session: Prostate Cancer Staging

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Monday, August 28, 2023

RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).

Key Points: 
  • RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 28, 2023 (GLOBE NEWSWIRE) --  – Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will present new clinical and preclinical data for 212Pb-VMT-α-NET, a Targeted Alpha-Particle Therapy, at the upcoming 36th Annual Congress of the European Association of Nuclear Medicine (EANM).
  • “Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics.
  • “We are particularly excited about the early clinical results from 212Pb-VMT-α-NET in patients suffering from different types of difficult-to-treat neuroendocrine tumors.
  • The data showed that fractionated doses of [212Pb]VMT-α-NET provided greater benefit than single dose administration of [212Pb]VMT-α-NET.